A Review of Human Studies Assessing the Efficacy of Cannabidiol for Anxiety Disorders
DOI:
https://doi.org/10.12775/QS.2025.38.58231Keywords
Anxiety, Cannabidiol (CBD), Post-traumatic stress disorder (PTSD), Social anxiety disorder (SAD), Human trialsAbstract
Anxiety disorders are the most commonly diagnosed mental disorders worldwide, and their prevalence continues to rise, leading to significant social and economic burdens. Recent interest has focused on CBD as a potential treatment. This systematic review assesses the current evidence on the efficacy of CBD in treating anxiety and related disorders, including post-traumatic stress disorder (PTSD), social anxiety disorder (SAD), and autism spectrum disorder (ASD). Unlike open-label trials prone to placebo bias, this study reviews randomized, double-blind, placebo-controlled trials. A review of literature was conducted using the Google Scholar database to gather information on "cannabidiol," specifically focusing on its relationship with "anxiety," "social anxiety disorder", "post-traumatic stress disorder” and ,,human trials." Positive outcomes were observed with 300 mg CBD doses, reducing anxiety in SAD patients, tremor in Parkinson’s disease, and anxiety in ASD and opioid-dependent individuals. Minimal improvements were noted in PTSD patients with sexual trauma. Further research is needed to clarify CBD’s therapeutic potential in diverse clinical contexts.
References
[1] F. Pellati, V. Borgonetti, V. Brighenti, M. Biagi, S. Benvenuti, i L. Corsi, „Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer”, BioMed Research International, t. 2018, nr 1, s. 1691428, 2018, doi: 10.1155/2018/1691428.
[2] L. Taylor, B. Gidal, G. Blakey, B. Tayo, i G. Morrison, „A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects”, CNS Drugs, t. 32, nr 11, s. 1053–1067, lis. 2018, doi: 10.1007/s40263-018-0578-5.
[3] D. L. de Almeida i L. A. Devi, „Diversity of molecular targets and signaling pathways for CBD”, Pharmacology Research & Perspectives, t. 8, nr 6, s. e00682, 2020, doi: 10.1002/prp2.682.
[4] M. M. Kenwood, N. H. Kalin, i H. Barbas, „The prefrontal cortex, pathological anxiety, and anxiety disorders”, Neuropsychopharmacol., t. 47, nr 1, s. 260–275, sty. 2022, doi: 10.1038/s41386-021-01109-z.
[5] Diagnostic and statistical manual of mental disorders: DSM-5, 5th ed. Washington: American psychiatric association, 2013.
[6] „Anxiety disorders”. Dostęp: 20 grudzień 2024. [Online]. Dostępne na: https://www.who.int/news-room/fact-sheets/detail/anxiety-disorders
[7] M. Di Luca i in., „Consensus Document on European Brain Research”, European Journal of Neuroscience, t. 33, nr 5, s. 768–818, 2011, doi: 10.1111/j.1460-9568.2010.07596.x.
[8] „Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders - ScienceDirect”. Dostęp: 11 grudzień 2024. [Online]. Dostępne na: https://www.sciencedirect.com/science/article/pii/S0163725814002332
[9] C. Ibeas Bih, T. Chen, A. V. W. Nunn, M. Bazelot, M. Dallas, i B. J. Whalley, „Molecular Targets of Cannabidiol in Neurological Disorders”, Neurotherapeutics, t. 12, nr 4, s. 699–730, paź. 2015, doi: 10.1007/s13311-015-0377-3.
[10] L. M. Bolsoni, J. A. S. Crippa, J. E. C. Hallak, F. S. Guimarães, i A. W. Zuardi, „The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event”, Braz. J. Psychiatry, t. 44, s. 298–307, doi: https://doi.org/10.1590/1516-4446-2021-2317.
[11] I. M. Linares i in., „Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test”, Braz. J. Psychiatry, t. 41, s. 9–14, paź. 2018, doi: https://doi.org/10.1590/1516-4446-2017-0015.
[12] M. M. Bergamaschi i in., „Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients”, Neuropsychopharmacol, t. 36, nr 6, s. 1219–1226, maj 2011, doi: 10.1038/npp.2011.6.
[13] S. M. De Faria i in., „Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease”, J Psychopharmacol, t. 34, nr 2, s. 189–196, luty 2020, doi: 10.1177/0269881119895536.
[14] N. Masataka, „Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders”, Front. Psychol., t. 10, lis. 2019, doi: 10.3389/fpsyg.2019.02466.
[15] Y. L. Hurd i in., „Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial”, AJP, t. 176, nr 11, s. 911–922, lis. 2019, doi: 10.1176/appi.ajp.2019.18101191.
[16] P. R. Gundugurti i in., „Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial”, Asian Journal of Psychiatry, t. 97, s. 104073, lip. 2024, doi: 10.1016/j.ajp.2024.104073.
[17] E. A. da Silva Junior i in., „Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial”, Trends Psychiatry Psychother, t. 46, s. e20210396, luty 2024, doi: 10.47626/2237-6089-2021-0396.
[18] M. H. N. Chagas i in., „Can anxiety increase tremors in patients with Parkinson’s disease? An experimental model”, Arch. Clin. Psychiatry (São Paulo), t. 44, s. 85–88, sie. 2017, doi: https://doi.org/10.1590/0101-60830000000126.
[19] I. Zahoor, A. Shafi, i E. Haq, „Pharmacological Treatment of Parkinson’s Disease”, Exon Publications, s. 129–144, grudz. 2018, doi: 10.15586/codonpublications.parkinsonsdisease.2018.ch7.
[20] S. Shannon, N. Lewis, H. Lee, i S. Hughes, „Cannabidiol in Anxiety and Sleep: A Large Case Series”, Perm J, t. 23, s. 18–041, sty. 2019, doi: 10.7812/TPP/18-041.
[21] S. Yamaori, K. Koeda, M. Kushihara, Y. Hada, I. Yamamoto, i K. Watanabe, „Comparison in the In Vitro Inhibitory Effects of Major Phytocannabinoids and Polycyclic Aromatic Hydrocarbons Contained in Marijuana Smoke on Cytochrome P450 2C9 Activity”, Drug Metabolism and Pharmacokinetics, t. 27, nr 3, s. 294–300, sty. 2012, doi: 10.2133/dmpk.DMPK-11-RG-107.
[22] A. W. Zuardi i in., „Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life”, Front. Pharmacol., t. 8, maj 2017, doi: 10.3389/fphar.2017.00259.
[23] E. M. Blessing, M. M. Steenkamp, J. Manzanares, i C. R. Marmar, „Cannabidiol as a Potential Treatment for Anxiety Disorders”, Neurotherapeutics, t. 12, nr 4, s. 825–836, paź. 2015, doi: 10.1007/s13311-015-0387-1.
[24] E. W. Leen-Feldner, T.-M. Bynion, R. Gournay, M. O. Bonn-Miller, i M. T. Feldner, „Practical considerations for testing the effects of cannabidiol on human anxiety”, Journal of Anxiety Disorders, t. 82, s. 102429, sie. 2021, doi: 10.1016/j.janxdis.2021.102429.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Kuba Borys Romańczuk, Katarzyna Kamińska-Omasta, Bartosz Omasta, Olga Krupa, Paulina Dorota Pietrukaniec, Zofia Martyna Wójcik, Kinga Furtak, Szymon Przemysław Stolarczyk, Magdalena Agata Czerska, Daria Rybak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 17
Number of citations: 0
